Metagenomi, Inc. Common Stock (MGX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
This page provides the complete earnings calendar, dividend schedule, and financial data for Metagenomi, Inc. Common Stock in 2026. The next earnings report is expected on November 18, 2026.
Metagenomi, Inc. Common Stock missed consensus estimates in its latest earnings report, with EPS of USD -0.73 below the USD -0.5531 estimate and revenue of USD -278.5 thousand missing the USD 3.01 million forecast by 109.3%. In the prior quarter both EPS and revenue likewise missed expectations, with revenue about 78.9% below the forecast.
Dividend calendar
No dividend history available.
EPS (Earnings Per Share)
Revenue
Company profile
Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.
